SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer.

Xiaofeng Chen,Xiaofeng Wu,Hao Wu,Qianwen Shao,Feipeng Zhu,Xiaofeng Qian,Fengjiao Zhao,Weidong Mao,Jing Sun,Jian Wang,Gaohua Han,Changxian Li,Poshita kumari Seesaha,Quanren Wang,Huajun Li,Yang Shao,Yanhong Gu,Xiangcheng Li,Yongqian Shu

SHR-1210 combined with GEMOX as first-line treatment in patients with advanced biliary tract cancer.

2020

Xiaofeng Chen
Xiaofeng Wu
Hao Wu
Qianwen Shao
Feipeng Zhu
Xiaofeng Qian
Fengjiao Zhao
Weidong Mao
Jing Sun
Jian Wang
Gaohua Han
Changxian Li
Poshita kumari Seesaha
Quanren Wang
Huajun Li
Yang Shao
Yanhong Gu
Xiangcheng Li
Yongqian Shu

535Background: This study aimed to evaluate the efficacy and safety of SHR-1210 (a humanized anti-programmed cell death receptor 1 antibody) plus gemcitabine and oxaliplatin (GEMOX) as first line t...

Keywords:

Gastroenterology
Cancer
first line
Biliary tract
Internal medicine
Medicine
Pathology
GemOx
in patient
Gemcitabine
Oxaliplatin
Oncology
Antibody
first line treatment
Programmed cell death
Receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations